Related Experiment Video

Updated: Jul 18, 2026

A Pre-Clinical Model of Synovitis Using Ex vivo Human Synovial Tissue with Preserved Function and Architecture
08:32

A Pre-Clinical Model of Synovitis Using Ex vivo Human Synovial Tissue with Preserved Function and Architecture

Published on: March 20, 2026

Synovial expression of vasoactive intestinal peptide in polymyalgia rheumatica

L Pulsatelli1, P Dolzani, T Silvestri

  • 1Laboratorio di Immunologia e Genetica, Istituti Ortopedici Rizzoli, Bologna, Italy.

Clinical and Experimental Rheumatology
|December 22, 2006
PubMed
Abstract

Insights

Vasoactive intestinal peptide (VIP) is significantly expressed in polymyalgia rheumatica (PMR) synovial tissue, potentially contributing to musculoskeletal discomfort and inflammation. Treatment reduced VIP-positive cells in the sublining area.

Area of Science:

  • Rheumatology
  • Immunology
  • Neuroscience

Background:

  • Polymyalgia rheumatica (PMR) is an inflammatory condition affecting the elderly, characterized by severe shoulder and pelvic girdle pain.
  • Synovitis and bursitis are common findings in affected joints.
  • Neuropeptides play roles in pain perception and inflammation modulation.

Purpose of the Study:

  • To investigate the role of neuropeptides, specifically substance P (SP), calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP), and somatostatin (SOM), in the pathophysiology of PMR.
  • To analyze the expression of these neuropeptides in the synovial tissue of PMR patients.

Main Methods:

  • Immunohistochemical analysis was used to examine synovial neuropeptide expression.
  • Two groups of PMR patients were studied: at disease onset and after corticosteroid treatment.
  • Synovial tissue from patients with rheumatoid arthritis (RA) and osteoarthritis (OA) served as controls.

Main Results:

  • Significant expression of VIP was observed in the synovial tissue of PMR patients and, to a lesser extent, in RA patients.
  • In PMR, VIP immunostaining was present in both the lining layer and sublining areas of the synovial tissue.
  • Corticosteroid treatment in PMR patients led to a near absence of VIP-positive cells in the sublining area, while lining layer expression remained similar.

Conclusions:

  • Local production of VIP in PMR synovial tissue may contribute to the characteristic musculoskeletal pain.
  • VIP may play a role in the immunomodulation of synovial inflammation in PMR.
  • VIP expression patterns change with corticosteroid treatment, suggesting a therapeutic target.

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

In Vitro Recording of Mesenteric Afferent Nerve Activity in Mouse Jejunal and Colonic Segments10:32

In Vitro Recording of Mesenteric Afferent Nerve Activity in Mouse Jejunal and Colonic Segments

Published on: October 25, 2016

Related Concept Videos

Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...